시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 폐암 진단 및 스크리닝 시장 보고서(2025년)
Lung Cancer Diagnostic And Screening Global Market Report 2025
상품코드 : 1824407
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

폐암 진단 및 스크리닝 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.5%를 나타내 36억 8,000만 달러로 성장할 것으로 예상됩니다. 예측 기간에 있어서의 성장은 폐암 이환율 증가, 조기 발견의 중시의 고조, 고위험 검진 프로그램의 확대, 맞춤형 의료로의 시프트, 정부의 대처, 자금 조달 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향은 신규 스크리닝법의 출현, 바이오마커 검사의 진보, 인공지능(AI)의 통합, 리퀴드 바이옵시 채용 증가, 조기 발견에의 중점화, 저선량 CT 스크리닝 프로그램의 확대 등입니다.

향후 5년간의 성장률 9.5%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 한국과 일본에서 조달하는 리퀴드 바이옵시 플랫폼과 저선량 CT 스캐너의 비용을 상승시키고, 암 진단을 지연시키고 방사선과의 지출을 증가시킴으로써 조기 발견 노력을 방해할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

폐암의 유병률 증가가 예측되기 때문에 폐암 진단 및 스크리닝 시장은 당분간 성장을 견인할 것으로 보입니다. 기침, 흉통, 호흡 곤란 등의 증상을 특징으로 하는 폐암은 폐 조직에서의 이상 세포의 무질서한 증식에 의해 특징지어지는 악성 질환입니다. 폐암의 진단 및 스크리닝 방법은 조기 발견에 중요한 역할을 하며, 절개 생검이나 기관지경 검사 등의 다양한 검사가 이용되고 있습니다. 2023년 1월 기준 미국암 협회의 데이터에 따르면 미국에서는 약 23만 8,340명이 새롭게 폐암을 앓았고 12만 7,070명이 사망했다고 보고되었습니다. 이 폐암 증례의 급증은 진단 및 스크리닝 대책의 중요성을 강조하고 폐암 진단 및 스크리닝 시장 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Lung cancer diagnosis and screening involve employing examinations and techniques to detect and identify lung cancer, aiming for early detection and accurate diagnosis to facilitate effective treatment planning. This process is commonly applied in the treatment of squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnostic and screening market size has grown strongly in recent years. It will grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to growth in digital imaging, standardization of screening protocols, public health initiatives against tobacco use, establishment of cancer registries, and advancements in pathology analysis.

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing incidence of lung cancer, growing emphasis on early detection, expansion of high-risk screening programs, shift towards personalized medicine, government initiatives and funding. Major trends in the forecast period include emergence of novel screening modalities, advancements in biomarker testing, integration of artificial intelligence (AI), rise in liquid biopsy adoption, focus on early stage detection, and expansion of low-dose CT screening programs.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper early detection efforts by increasing the cost of liquid biopsy platforms and low-dose CT scanners sourced from South Korea and Japan, thereby delaying cancer diagnosis and elevating radiology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Key players in the lung cancer diagnostic and screening market are advancing technologies such as lung cancer tests aimed at enhancing early detection, improving diagnostic accuracy, and enabling personalized treatment strategies for patients at high risk of the disease. These lung cancer tests utilize various methods, including imaging, biomarker analysis, and cytological examinations, to identify the presence of lung cancer. For example, in December 2023, Freenome, a biotechnology company based in the United States, introduced PROACT LUNG. This trial represents a significant advancement in lung cancer screening, potentially leading to earlier detection and improved patient outcomes while addressing current shortcomings in screening practices.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Diagnostic And Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lung cancer diagnostic and screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lung cancer diagnostic and screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lung Cancer Diagnostic And Screening Growth Analysis And Strategic Analysis Framework

6. Lung Cancer Diagnostic And Screening Market Segmentation

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

9. China Lung Cancer Diagnostic And Screening Market

10. India Lung Cancer Diagnostic And Screening Market

11. Japan Lung Cancer Diagnostic And Screening Market

12. Australia Lung Cancer Diagnostic And Screening Market

13. Indonesia Lung Cancer Diagnostic And Screening Market

14. South Korea Lung Cancer Diagnostic And Screening Market

15. Western Europe Lung Cancer Diagnostic And Screening Market

16. UK Lung Cancer Diagnostic And Screening Market

17. Germany Lung Cancer Diagnostic And Screening Market

18. France Lung Cancer Diagnostic And Screening Market

19. Italy Lung Cancer Diagnostic And Screening Market

20. Spain Lung Cancer Diagnostic And Screening Market

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

22. Russia Lung Cancer Diagnostic And Screening Market

23. North America Lung Cancer Diagnostic And Screening Market

24. USA Lung Cancer Diagnostic And Screening Market

25. Canada Lung Cancer Diagnostic And Screening Market

26. South America Lung Cancer Diagnostic And Screening Market

27. Brazil Lung Cancer Diagnostic And Screening Market

28. Middle East Lung Cancer Diagnostic And Screening Market

29. Africa Lung Cancer Diagnostic And Screening Market

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

34. Recent Developments In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기